Synthesis, characterization, radiolabeling and biodistribution of a novel cyclohexane dioxime derivative as a potential candidate for tumor imaging

Abstract

As a result of biodistribution studies, the newly synthesized cyclohexane dioxime derivative showed its good uptake in tumor cells, which affords a potential radiopharmaceutical that could be used as a good tumor imaging agent.

99mTc-Citrate-gold nanoparticles as a tumor tracer: Synthesis, characterization, radiolabeling and in-vivo studies

“…The pH of the reaction mixture must range from 6 to 8 to achieve convenient reduction and not affect the sensitive structures of nanoparticles [22] . At pH below or above the optimum value, the labeling yield was decreased (at pH 6 and 10 the labeling yield were 77.5 and 68.5 %, respectively) due to the formation of reduced hydrolyzed technetium colloid which is the main radiochemical impurity [23] . The content of citrate-AuNPs was also affecting the percent of labeling yield, the lower substrate amounts, the lower labeling yield due to its insufficient chelation with all the reduced 99m Tc species [24] .…”

Radioiodination of zearalenone and determination of Lactobacillus plantarum effect of on zearalenone organ distribution: In silico study and preclinical evaluation

“…scarification of animals was conducted after certain times (5 min, 15 min, 30 min, 60 min and 2 h) after injection. Organs were collected in addition to (Fresh blood, bone, and muscle tissues) then measured against prepared standard solution of the labeled substrate [ [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] , [89] , [90] , [91] , [92] , [93] , [94] , [95] , [96] , [97] , [98] , [99] , [100] ]. The mean percentage of the injected dose was calculated.…”

Common Shortcomings in Study on Radiopharmaceutical Design Research: A Case Study of 99mTc-Labelled Methotrexate

“…Therefore, studies on the stability of not isolated radiocomplex from labelling reaction mixture are conducted incorrectly providing adulterated results. Unfortunately, in many works it can be found that stability study of newly designed radiopreparation has been evaluated as changes of the labelling reaction yield over time [ 29 , 30 , 31 ]. Moreover, from an ethical point of view, only radiopreparations that fully meet all requirements for radiopharmaceuticals may be allowed for studies on animals obligatory before clinical trials.…”